MicroRNA 500b (MIR500B)

MicroRNA 500b (MIR500B) is a member of the microRNA family of small non-coding RNAs, typically 18–25 nucleotides in length, that regulate gene expression at the post-transcriptional level. MIR500B is processed from a precursor transcript producing mature microRNA via the canonical biogenesis pathway involving DROSHA and DICER enzymes. Like other microRNAs, it is implicated in fundamental biological processes including cell proliferation, differentiation, apoptosis, and disease pathogenesis. The functional outcome of MIR500B expression depends on the context and balance of its target gene networks: it may play roles in cancer as either a tumor suppressor or oncogene, interacting with diverse signaling pathways. While many microRNAs are explored as direct therapeutic targets and/or diagnostic biomarkers, specific clinical usefulness and molecular targets for MIR500B are still under investigation[1][2][3].

Other names

hsa-mir-500bmir-500bhsa-miR-500bMIR500B

Drugs targeting microRNAs typically act via antisense inhibition (miRNA inhibitors/antagomirs bind to and neutralize the microRNA) or mimic replacement (synthetic miRNA mimics restore regulatory function in deficient contexts).